Open an account

Precigen

PGEN · NASDAQ

$6.83+$0.17 (+2.55%)TodayMarket closed ·
Prev close $6.66

About PGEN

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 160 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Employees
160
Headquarters
Germantown, Maryland
Listed
Aug 8, 2013
Sector
Health Care
Industry
Biotechnology
Website
precigen.com

PGEN key statistics

Market cap
2.45B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.06M
Volume
6.17M
Open price
$6.62
High today
$6.95
Low today
$6.51
52 Week high
$8.98
52 Week low
$3.04

Precigen (PGEN) at a glance

As of Oct 20, 2026, Precigen (PGEN) shares are priced at $6.83, giving the company a market cap of 2.45B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.51 and $6.95. The current price is 4.9% above the day's low and 1.7% below its high.

Volume so far is 6.17M shares, above the average of 5.06M shares a day.

Over the past year Precigen has ranged from $3.04 to $8.98, and now sits 64% of the way up that range.

Precigen met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.05 per share against an estimate of -$0.0136.

The average analyst price target is $13.94, 104.1% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $13.94
Low
$11.11
Now
$6.83
High
$18.90

PGEN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 134.5% on average.

  1. Q3 FY24: reported -$0.09 per share against an estimate of -$0.0816
  2. Q4 FY24: reported -$0.06 per share against an estimate of -$0.0577
  3. Q1 FY25: reported -$0.07 per share against an estimate of -$0.0816
  4. Q2 FY25: reported -$0.09 per share against an estimate of -$0.0843
  5. Q3 FY25: reported -$1.06 per share against an estimate of -$0.0969
  6. Q4 FY25: reported -$0.07 per share against an estimate of -$0.085
  7. Q1 FY26: reported -$0.02 per share against an estimate of -$0.0326
  8. Q2 FY26: reported $0.05 per share against an estimate of -$0.0136

PGEN news

  • Press releasePRNewswire

    Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

  • Press releaseACCESS Newswire

    Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

  • Press releasePRNewswire

    Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

  • Press releasePRNewswire

    Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

  • Press releasePRNewswire

    Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

  • Press releasePRNewswire

    Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Similar companies

Companies in the same industry as Precigen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.